CI

At a glance

ClinicalIndex Comparison Record
Early Ph 1Completed· 12 enrolled
Drug / intervention
Perflutren Lipid Microspheres +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03297112
NCT03297112Early Ph 1Completed
CompareCT.gov

Subharmonic Contrast Ultrasound for Improved Characterization for Adnexal Masses-A Pilot Study

Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University·interventional·Posted Sep 29, 2017·Updated May 15, 2025

In Brief

A Early Phase 1 clinical trial evaluating Perflutren Lipid Microspheres and Contrast-Enhanced Subharmonic Ultrasound Imaging for Adnexal Mass. Completed, enrolled 12 participants across 1 site.

Detailed Summary

This pilot clinical trial studies how well contrast-enhanced subharmonic ultrasound imaging works in improving the characterization of adnexal masses in patients undergoing surgery. Contrast-enhanced subharmonic ultrasound imaging uses high-frequency sound waves to produce images of internal organs and when combined with an ultrasound agent such as perflutren lipid microspheres, may help improve imaging and management of adnexal masses.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdnexal Mass
CountriesUnited States
CollaboratorsNational Institutes of Health (NIH), Lantheus Medical Imaging

Timeline

Early Ph 1CompletedFinished
201820192020202120222023202420252026
First PostedSep 29, 2017
Enrollment StartAug 1, 2017
Primary CompletionSep 4, 2018
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 8.8 years ago

Interventions

Perflutren Lipid Microspheresdrug

Given IV

Contrast-Enhanced Subharmonic Ultrasound Imagingprocedure

Undergo contrast-enhanced subharmonic ultrasound imaging